SDAX candidate: Dermapharm brings 25% percent to the stock exchange

30. Janu­ary 2018

Berlin — The initial public offe­ring of Derm­a­ph­arm has star­ted. The offer period runs until Febru­ary 8. The manu­fac­tu­rer has set a range of 26 to 30 euros. The total volume of the offe­ring is thus expec­ted to be around EUR 350 to 404 million. Since Wilhelm Beier (photo), the company’s CEO, only wants to place 25 percent of the shares, he could make a good cut compared to the sale plan­ned in 2016.

A total of 13.455 million shares are to be offe­red to inves­tors. Of these, 3.84 million will come from a capi­tal increase and 7.86 million from Beier and his family. In addi­tion, an over-allo­t­­ment option (green­shoe) for 1.755 million shares owned by the company foun­der is plan­ned. Should all shares be sold, the free float would amount to appro­xi­m­ately 25 percent. Derm­a­ph­arm would thus be valued at 1.4 to 1.6 billion euros. The plan­ned sale to finan­cial inves­tors, which was later cancel­led, was worth 1.1 billion euros a year ago. Accor­ding to media reports, the finan­cial inves­tors BC Part­ners and Nordic Capi­tal each offe­red slightly more than one billion euros. .

The money raised in the IPO — around 100 to 115 million euros from the capi­tal increase — is to be used to expand a produc­tion faci­lity, and a new produc­tion plant is also to be built in Austria. Derm­a­ph­arm also intends to expand inter­na­tio­nally. Further acqui­si­ti­ons are plan­ned, as well as bran­ches in the Bene­lux count­ries and in the Czech Repu­blic and Slova­kia. For share buyers, 50 to 60 percent of profits are to be paid out as divi­dends in the very first year.

New products in the pipeline
New products are also spur­ring expan­sion, with 40 curr­ently in the plan­ning and imple­men­ta­tion stages. Of these, 28 are to be brought to market by 2023. In order to make itself look good for the IPO, Derm­a­ph­arm acqui­red two compa­nies, Tromms­dorff and Strath­mann, at the end of last year. Recently, Bio-Diät Berlin has also become part of Dermapharm.

About Derm­a­ph­arm
Derm­a­ph­arm manu­fac­tures off-patent drugs (gene­rics) and sells them prima­rily in Germany, a market which in and of itself can be conside­red very solid, albeit compe­ti­tive. The vitamin D prepa­ra­tion Dekris­tol 20,000 I.U. accoun­ted for around 7.5 percent of sales in 2016.

Subscribe newsletter

Here you can read about the latest transactions, IPOs, private equity deals and venture capital investments, who has raised a new fund, how Buy & Build activities are going.

Get in touch

Contact us!
fyb [at]